Releases
See all
Releases
11. February, 2021
Year-end report Q4-2020 – on track and accelerating clinical activities
Cessatech A/S today releases its results for the period 6. April – 31 December 2020. The company is on track with Q4 activities and getting...
Releases
21. January, 2021
Supporting ‘Save the Children’
Cessatech has entered a corporate sponsorship with Save the Children. We want to make...
Releases
27. November, 2020
Cessatech’s IPO of units significantly oversubscribed
Subscribed to DKK 107 million, corresponding to a subscription ratio of approx. 680 percent....
Releases
6. November, 2020
Approval for IPO listing
Cessatech A/S today announces that Spotlight Stock Market’s listing committee has approved Cessatech’s application...
Releases
18. August, 2020
Strong profiles to the Board
The Board has a wide experience from the entire value chain, which is a strong asset for Cessatech and its future aspirations
Facts about Children
See all
Facts
2. February, 2021
Ny forskning: Barn bör få smärtlindring vid vaccinationer och injektioner
Barn mår bra av smärtlindring vid vanliga vaccinationer och injektioner. Det säger den senaste...
Facts
31. August, 2020
DR.dk focus – Børn og ældre får medicin, der ikke er godkendt til dem
Kan give voldsomme bivirkninger, når børn og ældre får medicin, der ikke er godkendt til dem...
Facts
5. June, 2020
High off-label use in Children
Studies are still needed to determine the safety and efficacy of drugs that lack FDA labeling for this vulnerable patient population. Drugs were administered off-label...
Facts
1. May, 2020
Children are not small adults
Children differ pharmacokinetically from adults, and medication for adults cannot simply be administered in smaller doses
Experience
Proven track-record within drug development and product launches, in Europe, US and Asia.
The executive management team and the Board of Directors have a proven track-record within drug development, paediatric analgesic research, product launches and capital raising across all major markets.
Team
Lead Asset
CT001 – Nasal spray
Cessatech’s first product and lead asset, CT001, is an analgesic non-invasive nasal spray for children aged 1-17 years that experience acute pain or pain related to medical procedures. Today’s analgesic solutions often require an intravenous access which is not always feasible or easy and can be painful experience.
See details
Stay up to date!
Subscribe and get notified on Cessatech's latest news.